New antibiotics expected for resistant pneumonia bugs

Darrell Miller

10/10/05

Date: October 10, 2005 11:52 AM
Author: Darrell Miller (dm@vitanetonline.com)
Subject: New antibiotics expected for resistant pneumonia bugs

New antibiotics expected for resistant pneumonia bugs

Scientists recently announced the expected arrival of a new family of bacteria-killers on the horizon for pneumonia and other diseases. These new antibiotics should offer an alternative to standard antibiotics, many of which have lost their punch against increasingly resistant germs.

The standard treatment today for many bacterial infections that cause respiratory diseases are medicines called macrolides. These include well-known antiobiotics like penicillin and erythromycin. However, certain bacteria strains are growing resistant to them, as well as to the primary back-up medicines, known as quinolones.

The pharmaceutical industry's response to this problem is ketolides. Ketolides are derived from macrolides, but since they have a different chemical composition, they will kill bacteria that are resistant to macrolides. Researchers recently presented reports on two varieties of ketolides at an infectious diseases meeting sponsored by the American Society for Microbiology. Aventis Pharmaceuticals recently filed with the U.S. Food and Drug Administration to gain permission to sell a new ketolide antibiotic, Ketek, or telithromycin. A similar drug made by Abbott Pharmaceuticals, code named ABT-773, is also in the early stages of human testing.

Researchers presented new Ketek studies involving 2,500 patients. These reports intended to show how the once-a-day Ketek is equally effective as other standard antibiotics in treating many bacterial diseases, including pneumonia, bronchitis, sinus infections and sore throats. Scientist also say since the Ketek treatment lasts just five days, which is shorter than most antibiotic treatments, bacteria may be less likely to grow resistant to the new drug.

--
Discount vitamins at Vitanet ®